Deutsche Bank AG Buys 246,703 Shares of Dyne Therapeutics, Inc. $DYN

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Deutsche Bank AG raised its stake in Dyne Therapeutics, Inc. (NASDAQ:DYN - Free Report) by 347.7% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 317,664 shares of the company's stock after acquiring an additional 246,703 shares during the quarter. Deutsche Bank AG owned about 0.28% of Dyne Therapeutics worth $3,323,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its position in Dyne Therapeutics by 10.5% in the 1st quarter. Vanguard Group Inc. now owns 7,406,344 shares of the company's stock valued at $77,470,000 after acquiring an additional 702,418 shares in the last quarter. Janus Henderson Group PLC increased its position in Dyne Therapeutics by 8.3% in the 4th quarter. Janus Henderson Group PLC now owns 7,379,309 shares of the company's stock valued at $173,808,000 after acquiring an additional 566,146 shares in the last quarter. Jefferies Financial Group Inc. acquired a new stake in Dyne Therapeutics in the 4th quarter valued at about $42,408,000. Orbimed Advisors LLC increased its position in Dyne Therapeutics by 73.2% in the 4th quarter. Orbimed Advisors LLC now owns 1,227,080 shares of the company's stock valued at $28,910,000 after acquiring an additional 518,680 shares in the last quarter. Finally, ArrowMark Colorado Holdings LLC increased its position in Dyne Therapeutics by 3.6% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 932,231 shares of the company's stock valued at $21,963,000 after acquiring an additional 32,041 shares in the last quarter. Institutional investors and hedge funds own 96.68% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on DYN shares. JPMorgan Chase & Co. lowered their price objective on shares of Dyne Therapeutics from $10.00 to $9.00 and set a "neutral" rating for the company in a research report on Tuesday, July 15th. HC Wainwright lowered their price target on shares of Dyne Therapeutics from $46.00 to $38.00 and set a "buy" rating for the company in a research report on Friday, May 9th. Jones Trading began coverage on shares of Dyne Therapeutics in a research report on Thursday, June 26th. They set a "buy" rating and a $30.00 price target for the company. Oppenheimer lowered their price target on shares of Dyne Therapeutics from $34.00 to $13.00 and set an "outperform" rating for the company in a research report on Wednesday, August 6th. Finally, Robert W. Baird lowered their price target on shares of Dyne Therapeutics from $46.00 to $32.00 and set an "outperform" rating for the company in a research report on Wednesday, June 18th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $33.80.

Dyne Therapeutics Trading Up 2.9%

NASDAQ DYN traded up $0.36 during trading on Friday, reaching $12.58. 2,298,424 shares of the stock traded hands, compared to its average volume of 3,077,638. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -3.26 and a beta of 1.08. The stock's 50-day moving average price is $10.23 and its 200 day moving average price is $11.20. The company has a quick ratio of 16.83, a current ratio of 16.83 and a debt-to-equity ratio of 0.17. Dyne Therapeutics, Inc. has a fifty-two week low of $6.36 and a fifty-two week high of $46.81.

Dyne Therapeutics (NASDAQ:DYN - Get Free Report) last issued its quarterly earnings data on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.99) by $0.02. Analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Insider Transactions at Dyne Therapeutics

In other news, CEO John Cox acquired 100,000 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The stock was purchased at an average price of $9.11 per share, for a total transaction of $911,000.00. Following the completion of the acquisition, the chief executive officer owned 242,179 shares in the company, valued at $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 14.14% of the company's stock.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.